Netherlands: AstraZeneca to acquire Neogene for up to US$320m

Global biopharmaceutical company, AstraZeneca, is to acquire Neogene Therapeutics, a global clinical-stage biotechnology company with EU headquarters in Amsterdam. Neogene is focused on discovering, developing and manufacturing next-generation, transformative TCR therapies targeting neoantigens in solid cancers. The total consideration could reach US$320m, which will include an initial payment of US$200m, and a further payment of…

You must be a HMI Subscriber to view this content.

Subscribe Now »